Log In
Print
BCIQ
Print
Print this Print this
 

CEQ508

  Manage Alerts
Collapse Summary General Information
Company Marina Biotech Inc.
DescriptionOral RNAi targeting beta-catenin (CTNNB1) delivered using transKingdom RNAi (tkRNAi) technology
Molecular Target Beta-catenin (CTNNB1)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPhase I/II
Standard IndicationAdenomatous polyps
Indication DetailsTreat familial adenomatous polyposis (FAP)
Regulatory Designation U.S. - Orphan Drug (Treat familial adenomatous polyposis (FAP))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$31.6M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today